cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Roivant Sciences Ltd
2 own
3 watching
Current Price
$0
$0.18
(2.23%)
logo-roiv
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
5,846.41M
52-Week High
52-Week High
10
52-Week Low
52-Week Low
2.52
Average Volume
Average Volume
0.73M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization5,846.41M
icon52-Week High10
icon52-Week Low2.52
iconAverage Volume0.73M
iconDividend Yield--
iconP/E Ratio--
What does the Roivant Sciences Ltd do?
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Read More
How much money does Roivant Sciences Ltd make?
News & Events about Roivant Sciences Ltd.
Globe Newswire
2days ago
Quarterly investor call and webcast scheduled on Monday, February 13 at 8:00 a.m. ETRoivant will also participate in the SVB Securities Global Biopharma Conference in February and the Cowen 43rd Annual Health Care Conference in March BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Jan. 30, ...
PR Newswire
1month ago
Thinking about buying stock in Prometheus Biosciences, Meta Materials, Eterna Therapeutics, Roivant Sciences, or China Automotive Systems? Thinking about buying stock in Prometheus Biosciences, Meta Materials, Eterna Therapeutics, Roivant Sciences, or China Automotive Systems? PR Newswire NEW YORK...
Globe Newswire
2 months ago
Roivant to develop PF-06480605 (now RVT-3101), a potential first in class, fully human monoclonal antibody that blocks tumor necrosis factor-like ligand 1A (TL1A), a cytokine believed to play a key role in inflammation and fibrosisRVT-3101 is currently being evaluated in a large global Phase 2b ...
Ticker Report
2 months ago
Roivant Sciences Ltd. (NASDAQ:ROIV Get Rating) Director Financial Lp Qvt sold 5,656,081 shares of the stock in a transaction that occurred on Thursday, November 10th. The stock was sold at an average price of $4.75, for a total transaction of $26,866,384.75. Following the transaction, the ...
Globe Newswire
2 months ago
NEW YORK and BASEL, Switzerland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Affivant, a biotechnology company dedicated to developing novel immune-oncology approaches to activate and enable the innate immune system to fight cancer, will present a poster at the 37th Annual Meeting of The Society for ...
Frequently Asked Questions
Frequently Asked Questions
What is Roivant Sciences Ltd share price today?
plus_minus_icon
Can Indians buy Roivant Sciences Ltd shares?
plus_minus_icon
How can I buy Roivant Sciences Ltd shares from India?
plus_minus_icon
Can Fractional shares of Roivant Sciences Ltd be purchased?
plus_minus_icon
What are the documents required to start investing in Roivant Sciences Ltd stocks?
plus_minus_icon
What is today’s traded volume of Roivant Sciences Ltd?
plus_minus_icon
What is today’s market capitalisation of Roivant Sciences Ltd?
plus_minus_icon
What is the 52-Week High and Low Range of Roivant Sciences Ltd?
plus_minus_icon
What percentage is Roivant Sciences Ltd down from its 52-Week High?
plus_minus_icon
What percentage is Roivant Sciences Ltd up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.18
(2.23%)
logo-roiv
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00